Could multimodal AI help identify which patients with early-stage HR+ breast cancer may benefit from extended endocrine therapy? In an NSABP B-42 cohort, significant benefit was observed in about one-quarter of patients the models classified as both high risk for late distant recurrence and likely to benefit from extended therapy. #ESMOAI26. ow.ly/Rqh15101alG

Long Road Home: The Continuing Journey of Metastatic Disease. Co-authored by @GeorgeSledge51. Read the full article. bit.ly/3R4m8g6

Long Road Home: The Continuing Journey of Metastatic Disease. asco.altmetric.com/details/1… Please see, and I hope enjoy, my new JCO OP editorial on where we sit with metastatic cancer.

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs for @YaleCancer cancerletter.com/in-brief/20…

Every ASCO has some hidden pearls. One that I had the luck to attend was a presentation by Gil Shamai on the discordance between AI prediction and standard path features — wonderfully discussed by David Rimm. Highly recommended. “AI errors are not bugs, but rather features”

A care model led by Manali Patel, MD, MPH, a Stanford thoracic oncologist, demonstrated that trained lay health staff can improve patient experiences, reduce emergency department visits, and lower overall #healthcare costs. ow.ly/4xlG50YW66U

🧠 #SABCS25: #AI models outperformed standard tools for predicting distant recurrence in patients with early-stage #BreastCancer, enabling more individualized risk assessment and treatment decision guidance. 👨‍⚕️ @jsparano | Eleftherios Mamounas, MD 🔗 ascopost.com/news/december-2…

Possible mechanisms of resistance to T-DXd in breast cancer patients using real-world data and multiomic profiling ⬆️ABCC1 and ⬇️ERBB2 showed ⬇️OS, in line with previous works on T-DXd. Presented at #SABCS24, now published on @Nature_NPJ by @GeorgeSledge51 et al. (link below)

A Real-World Experience in Pan-Tumor Testing for HER2 IHC in More Than 65 000 Solid Tumors jamanetwork.com/journals/jam… Trastuzumab deruxtecan-nxki (T-DXd) received tumor-agnostic FDA approval in April 2024 for adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors lacking other treatment options, based on responses seen across three DESTINY trials. This prompted widespread HER2 IHC testing across tumor types, leading to the first large-scale report on real-world HER2 IHC 3+ prevalence using standardized interpretation criteria. Among over 65,000 tested patients, HER2 IHC 3+ rates varied widely by cancer type, with #BladderCancer showing the highest prevalence (13.9%), while others—like gliomas, sarcomas, #ProstateCancer, and kidney cancers—had minimal or no expression. These findings suggest universal HER2 testing may not be necessary for all solid tumors, and a more targeted approach—initiating HER2 IHC only after identifying ERBB2 amplification or overexpression via comprehensive genomic profiling—could reduce unnecessary testing while optimizing workflow and cost-efficiency. Dave Bryant Rebecca Feldman Farah Abdulla Daniel Magee Jennifer R. Ribeiro Matthew Oberley Milan Radovich David Spetzler @carisls @GeorgeSledge51

Caris has published a 295,000+ patient study revealing variable efficacy among cancers for patients treated with tissue-agnostic drugs and uncovering the potential for expanding approvals to other drugs in the same class. Learn more: ow.ly/Ii5x50VlbqJ

Triple Negative Breast Cancer is a complex and aggressive form of breast cancer. Ahead of Triple Negative Breast Cancer Awareness Month, what is one thing you wish others were aware about living with TNBC? Share your experiences in the comments 👇 #TNBCFoundation #TNBC

Caris Chief Scientific Officer Milan Radovich, PhD, shares insights on how Caris Assure sets a new benchmark in #liquidbiopsy profiling. Join us in transforming patient care through innovative solutions: ow.ly/4LGf50TVt28

This week, we highlighted two recent collaborative publications by researchers, including @EHeath4100, @KelseyAPoorman, @JoanneXiu, @SamuelKareffMD, @marshalj23, @saikatbib, @Marindoc, @jpshen_md and others published in @BrJCancer and @CRC_AACR. bit.ly/3zlVK8H.

RT @caswell_jin: In addition to our paper ja.ma/47EB7zR, I’d also like to point you to the editorial jamanetwork.com/journals/jam… and…

Also for TROPION 01, obviously need OS. For field as a whole we could use structured crossover trials from ADC1–>ADC2. And we need a better understanding of resistance: resistance based on target vs payload.

TROPION Breast01 updated from October ESMO shows 2.4 mo improvement in PFS vs ineffective late line CT with improved QOL vs CT. Question: should we require, going forward, comparisons vs other ADCs rather than vs essentially inactive CT?

Monarch 3 frontline OS results for Abema continue to show numerically impressive improvements but a significant p value remains frustratingly elusive. This is confusing given positive second line and adjuvant results.

With both neoadjuvant Nivo and Pembro in ER pos BC pCR rates increase strongly as PD-L1 increases. Two questions: should we use PD-L1 as a predictive biomarker, and should we use either of these drugs in the absence of solid EFS improvements?

A press release on our recent study: med.stanford.edu/news/all-ne…

Excited to see our paper on antibiotics and triple-negative breast cancer mortality just published in Nature Communications: rdcu.be/c9Nkz.